The Calciphylaxis Treatment Market size on a global scale experienced significant growth in 2021 and is projected to continue expanding at a rapid pace throughout the forecast period. One of the major factors driving the revenue growth of the calciphylaxis treatment market is the increasing prevalence of cardiovascular calcification among patients with end-stage renal disease.

Calciphylaxis is a rare, painful, and often fatal condition that primarily affects individuals with moderate to severe kidney impairment. This condition leads to the accumulation of calcium deposits in the blood vessels, resulting in the obstruction of blood flow and the deterioration and death of skin and tissue in the affected areas. In some rare cases, the calcium deposits can develop internally in organs such as the eyes, lungs, brain, muscles, and intestines. Patients with calciphylaxis require specialized care, including wound management, and the presence of this condition is associated with hyperparathyroidism.

Get a free sample PDF of the report, visit @ https://www.reportsanddata.com/download-free-sample/5873

Calciphylaxis causes the formation of blood clots and severe skin ulcers, which can lead to life-threatening infections. It is commonly observed in individuals with renal failure who are on dialysis or have undergone kidney transplantation. The symptoms of calciphylaxis include pain, lesions, ulcers, calcification of the heart and major blood vessels, vision problems, internal bleeding, and muscle damage.

Factors Supporting Market Growth: Drivers: Hyperparathyroidism is a major driver of calciphylaxis, characterized by dysregulation of calcium and phosphorus metabolism. The treatment of calciphylaxis involves a multidisciplinary approach, which includes nephrology, dermatopathology, dermatology, pain management, and nutrition. The rising prevalence of kidney diseases and end-stage renal illnesses further contributes to the demand for effective calciphylaxis treatment, aiming to prevent recurrent hospitalizations and morbidity.

According to the International Society of Nephrology, the global prevalence of chronic kidney disease was reported to be 10.4% in males and 11.8% in females in November 2020. Acute kidney injury affects approximately 13.3 million individuals annually, and it can either resolve or progress to chronic kidney disease or kidney failure, leading to increased healthcare expenditure for the treatment of these conditions. These factors are expected to drive further revenue growth in the calciphylaxis treatment market during the forecast period.

Restraints: The lack of effective treatment options for calciphylaxis is a major factor restraining the revenue growth of the global market. Additionally, the high cost associated with these treatments negatively impacts the market as a majority of the population may face financial constraints in affording them. The affordability issue is expected to hinder the revenue growth of the calciphylaxis treatment market globally during the forecast period.

Opportunities: The increasing number of clinical studies being conducted presents significant opportunities for market revenue growth in the future. Collaborations between companies and research institutes are expanding, facilitating the advancement of clinical studies in various locations. For example, in June 2020, Chinook Therapeutics and Aduro Biotech, both investigating different approaches to the same rare disease, joined forces to merge their operations into a single company focused on discovering innovative kidney treatments.

Geographic Market Scenario: Largest Market Share: North America is expected to dominate the market in terms of revenue share during the forecast period. This can be attributed to significant developments in the healthcare sector, a strong economic environment, and the focus of research institutes on developing advanced technologies and treatment methods. The presence of modern hospital infrastructure and the availability of skilled healthcare professionals further contribute to market expansion. In March 2022, Lupin announced the launch of Sevelamer Hydrochloride tablets (800 mg) for the treatment of hyperphosphatemia in chronic kidney disease patients, following approval from the USFDA.

To know more about the latest insights of the report, visit @

https://www.reportsanddata.com/request-latest-insight/5873

Fastest Growing Region: The Asia Pacific region is anticipated to exhibit the highest revenue growth rate over the forecast period. This can be attributed to the presence of several developing countries such as India and China, which are actively promoting the expansion of their healthcare industries. The growing patient population in these emerging economies will drive the demand for various diagnostic and treatment approaches, thereby fostering market revenue growth. Additionally, there is a significant focus on popular therapeutic medications, particularly those aimed at reducing calcium-phosphorus levels in patients. These factors are expected to contribute to the rapid revenue growth rate in the Asia Pacific region.

Key Market Trends and Innovations: Kidney disease is a global health concern affecting over 10% of the world's population and more than half of individuals over the age of 70 in the United States. Clinical trials are being conducted to evaluate the efficacy of pirfenidone in preventing the progression of chronic kidney disease. The results of these trials, expected by December 2024, have the potential to significantly impact the global revenue of the calciphylaxis treatment market.

Organic and Inorganic Strategies Adopted: Companies in the calciphylaxis treatment market have adopted various strategies to expand their market presence. For example, Opko Health, Inc. announced the commercial release of Rayaldee in Germany in February 2022, in collaboration with Vifor Fresenius Medical Care Renal Pharma. Vifor Pharma has also made significant acquisitions, such as Sanifit Therapeutics and Inositec AG, to enhance its portfolio in the field of treatments for vascular calcification disorders associated with end-stage kidney disease. AstraZeneca received a license for Forxiga in the European Union for the treatment of chronic kidney disease in individuals with and without Type 2 Diabetes in August 2021. Sanifit, a clinical-stage biopharmaceutical company, successfully dosed the first patient in its pivotal phase 3 trial of SNF472, a treatment for calciphylaxis, in February 2020.

Major Companies in the Market: Several prominent companies operate in the calciphylaxis treatment market, including Amgen Inc., Vifor Pharma Management Ltd., AstraZeneca plc, Opko Health Inc., Lupin, Chinook Therapeutics Inc., Baxter, GlaxoSmithKline plc, Bayer AG, Takeda Pharmaceutical Company Ltd., Pfizer Inc., Astellas Pharma Inc., Novartis AG, Sanofi, Merck and Co., Inc., and others.

In conclusion, the calciphylaxis treatment market has experienced significant growth and is expected to continue expanding in the coming years. The increasing prevalence of kidney diseases, along with the lack of effective treatment options, presents both opportunities and challenges for market players. North America currently holds the largest market share, while the Asia Pacific region is projected to exhibit the fastest growth rate. Ongoing clinical studies and strategic collaborations are driving innovation in the field, leading to the development of new treatment approaches.

Request a customized copy of the report @

https://www.reportsanddata.com/request-customization-form/5873

Thank you for reading our report. To inquire about customization or any query about the report, please get in touch with us. Our team will make sure the report is best suited to your needs.  

Browse for more reports:

https://www.reportsanddata.com/report-detail/epinephrine-market

https://www.reportsanddata.com/report-detail/vitamin-d3-market

https://www.reportsanddata.com/report-detail/dry-mouth-relief-market

https://www.reportsanddata.com/report-detail/bioreactors-and-fermenters-market

https://www.reportsanddata.com/report-detail/x-ray-detectors-market

About Reports and Data 

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behaviour shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Contact:

John W, Head of Business Development
Reports And Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com
LinkedIn | Twitter | Blogs